Skip to main content
Intended for healthcare professionals

Abstract

Over the last decade there have been further developments in our knowledge of the risks and benefits of benzodiazepines, and of the risks and benefits of alternatives to benzodiazepines. Representatives drawn from the Psychopharmacology Special Interest Group of the Royal College of Psychiatrists and the British Association for Psychopharmacology together examined these developments, and have provided this joint statement with recommendations for clinical practice. The working group was mindful of widespread concerns about benzodiazepines and related anxiolytic and hypnotic drugs. The group believes that whenever benzodiazepines are prescribed, the potential for dependence or other harmful effects must be considered. However, the group also believes that the risks of dependence associated with long-term use should be balanced against the benefits that in many cases follow from the short or intermittent use of benzodiazepines and the risk of the underlying conditions for which treatment is being provided.

Get full access to this article

View all access and purchase options for this article.

Further Reading

Baldwin DS, Anderson IM, Nutt DJ, et al. (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19: 567–596.
Chick J, Nutt DJ (2011) Substitution therapy for alcoholism: Time for a reappraisal? J Psychopharmacol 26: 205–212.
Dell’osso B, Lader M (2013) Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 28: 7–20.
Lingford-Hughes A, Welch S, Peters L, et al. (2012) BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP. J Psychopharmacol 26: 899–952.
Nutt DJ, Sharpe M (2008) Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol 22: 3–6.
Stephens DN, King SL (2013) Neuropharmacology of Benzodiazepines. In: Blume AW, Kavanagh DJ, Kampman KM, et al. (eds) Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders. San Diego, USA: Academic Press, pp.605–614.
Wilson SJ, Nutt DJ, Alford C, et al. (2010) British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 24: 1577–1600.